InMed selects IVT formulation for INM-089 in dry AMD; preclinical data shows 10x safety margin

InMed Pharmaceuticals Inc.

Selected intravitreal (IVT) formulation for INM-089 as drug candidate for dry age-related macular degeneration (AMD).
Preclinical studies demonstrated successful delivery at doses up to 10 times projected therapeutic level, indicating favorable PK and safety margin.
Completed dose-ranging in vivo studies to guide dose selection for pivotal preclinical toxicology studies.
Intravitreal injection is established method for drug delivery to back of eye; overcomes challenges of topical formulations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.